Sage Therapeutics Set for Breakout on Upcoming Trial Results
AI Prediction of Sage Therapeutics, Inc (SAGE)
Sage Therapeutics is poised for a significant breakout due to upcoming catalysts in its clinical pipeline. The company's focus on brain health medicines, particularly for depression and neuropsychiatry, positions it well in a high-demand market. Sage's strategic collaborations and recent upgrades in analyst ratings suggest a positive trajectory, making it an attractive investment before key trial completions.
SAGE Report Information
Prediction Date2025-07-03 02:07:56
Close @ Prediction$9.20
Mkt Cap581m
IPO Date2014-07-18
AI-derived Information
Recent News for SAGE
- Jul 31 — Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up (Zacks)
- Jul 31 — Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics (GlobeNewswire)
- Jul 30 — Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
- Jul 30 — Sage Therapeutics Announces Second Quarter 2025 Financial Results (Business Wire)
- Jul 28 — Biogen Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
- Jul 28 — Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer (GlobeNewswire)
- Jul 25 — ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression (GlobeNewswire)
- Jul 10 — Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity (Investor's Business Daily)
- Jul 1 — What Makes Sage Therapeutics (SAGE) a New Buy Stock (Zacks)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.